Julie Beck
Analyst · Deutsche Bank
Thanks, John, and good morning, everyone. Let's take a look at our second quarter financial performance found on Slide 12. We demonstrated solid execution in a dynamic environment, including significant supply chain challenges and continued inflation with reported sales of $1.1 billion, up 4% year-over-year, primarily due to increased prices. Foreign currency translation negatively impacted sales by $51 million or approximately 5% in the quarter as the euro and British pound weakened against the dollar. Gross margins declined by 250 basis points in the quarter as pricing actions partially offset cost increases. The year-over-year gross margin decline was in our AWP business, however, margins in this business did improve sequentially. MP was able to effectively overcome cost increases with pricing actions. Although the inflationary environment continues, SG&A was flat to prior year. SG&A percent of sales at 10.1% decreased by 40 basis points from the prior year as business investment was offset by continued strict expense management and favorable foreign exchange translation. Operating margin of 9.6% was down 220 basis points compared to the prior year and up 220 basis points sequentially from increased pricing and disciplined cost control. We are pleased with achieving a 39% incremental margin improvement from the first quarter. Although price/cost dynamics have improved sequentially from the first quarter, operating profit in the second quarter of $104 million decreased $19 million from the prior year as price realization was offset by continued cost increases, manufacturing inefficiencies caused by supply chain disruptions, and the negative impact of changes in foreign exchange rates. Current quarter operating profit includes $1 million of charges in corporate and other associated with the litigation settlement on a former product line. Interest and other expense was approximately $21 million lower than Q2 of 2021, as we recorded a $26 million loss on early extinguishment of debt related to refinancing a significant portion of our capital structure and prepayment of term loans in the prior year. We also had an unfavorable year-over-year foreign exchange variance of $4 million. The second quarter global effective tax rate was approximately 17%. The slightly higher tax rate is primarily due to lower favorable discrete benefit in the current quarter, largely offset by reduced tax on the geographic distribution of income. Second quarter earnings per share of $1.07 increased $0.05 over last year and reflects an unfavorable EPS impact of $0.09 from foreign exchange translation. Also in the prior year, we had $0.26 of unfavorable financial callout, primarily in connection with the refinancing of a significant portion of the capital structure. Our return on invested capital remains strong at 17.3% as we continue to invest in the business and return cash to shareholders through share repurchases and dividends. Free cash flow for the quarter of $44 million was consistent with our expectations for the second quarter. I will discuss free cash flow in more detail later in my prepared remarks. Let's look at our segment results, starting with our Materials Processing segment found on Slide 13. MP had an excellent quarter with sales of $481 million, up 9% compared to the second quarter of 2021 with growth across all product lines. On a foreign exchange neutral basis, sales were up 16%. The business ended the quarter with a backlog of $1.1 billion, up 32% from a year ago. The strong backlog supports our sales outlook and is approximately 3x historical norms. We also have $100 million of additional backlog delivered beyond 12 months. In these challenging markets, MP increased their operating profit to 16.5% and increased their margins 230 basis points from the first quarter. MP has been able to demonstrate strong performance even in this inflationary environment with approximately 20% incremental margins on a reported and operational basis, excluding FX. The team continues their excellent operational execution. On Slide 14, we see our Aerial Work Platform segment financial results. AWP sales of $598 million were slightly higher compared to the prior year, increasing 4% on an FX-neutral basis. Backlog at quarter end was a record $2.3 billion, up 62% from the prior year. Both Genie and utilities have taken multiple price actions over the course of 2021 and 2022 to address inflationary cost pressures. In addition, both businesses have been battling parts shortages constraining their growth. AWP delivered operating margins of 7.7% in the quarter, down from last year by 330 basis points, but up sequentially from the first quarter of 2022 by 180 basis points. The sequential improvement was a result of strong execution on strict expense management and disciplined pricing actions. Please see Slide 15 for an overview of our disciplined capital allocation strategy. Free cash flow for the quarter was $44 million and consistent with our expectations. Free cash flow includes $38 million of IRS refunds, but was negatively impacted by $63 million of hospital inventory as well as unfavorable foreign exchange. Now let me detail some usage of our cash in the quarter. We continue to reinvest in our business with capital expenditures, acquisitions and technology investments of $32 million. A large portion of our capital expenditures is related to our Monterrey, Mexico facility, which remains on schedule. In addition, we prepaid $23 million of our term loan, reducing the outstanding balance to $55 million. Returning cash to shareholders is an important element of our disciplined capital allocation strategy. The company continued its quarterly dividend per share of $0.13, an 8.3% increase over the prior year. We also repurchased $61 million of shares in the quarter as we believe that Terex shares are an attractive investment. We have $61 million remaining on our share repurchase program. The company's strong balance sheet has allowed us to return approximately $100 million of cash to shareholders year-to-date. The company has significantly delevered over the past 4 years and strengthened its balance sheet. Outstanding gross debt has been reduced by $524 million since the second quarter of 2019, a 39% decrease, and $66 million since the second quarter of 2021 or a 7% increase. We have no near-term maturities until 2024, and 72% of our debt is at a fixed rate of 5% until the end of the decade. Our net leverage remains low at 1.56x, which is well below our 2.5x target through the cycle. We have ample liquidity of $678 million. The company is in an excellent position to run and grow the business. Now turning to Slide 16 and our full year outlook. Thanks to the strong execution of our team members and our robust backlog, we are raising our 2022 outlook that we shared with you in February and April. We expect earnings per share of $3.80 to $4.20 on sales of $4.1 billion to $4.3 billion. This outlook incorporates an additional unfavorable $0.25 per share due to foreign exchange from our initial outlook. Supply chain challenges, inflation pressures, geopolitical uncertainty, and highly restrictive China COVID policies continue, but the team has successfully navigated these challenges for the first half of 2022 and we expect continued improvement in price/cost dynamics throughout the year. Our strong backlog supports our sales outlook, which in total remains unchanged and reflects the ongoing dialogue with our suppliers. Sales are not a function of demand, but rather the ability of the supply chain to deliver components. We have the internal capacity to produce more, which we have demonstrated in the past. For the full year, our sales growth is based upon improved price execution of approximately 9%, volume growth of 6%, partially offset by unfavorable FX of 6%. SG&A cost management has been excellent, and we have reduced our full year outlook to 10.6% of sales. Interest and other expense increased $5 million on higher interest rates and unfavorable FX. Our global effective tax rate for the year has been reduced to 20% based on a more favorable full year geographic mix. We estimate a share count of approximately 70 million based on repurchase activities in the current year. We continue to expect sequential free cash flow improvement in the second half, but have lowered our full year outlook to $150 million to $200 million as a result of negative foreign exchange. Corporate and other loss has been increased to $80 million. Operating expenses are in line with our initial outlook. However, results have been adversely impacted by unfavorable foreign exchange and $7 million of year-to-date financial callout associated with restructuring, severance and litigation settlement expenses on former product lines. We expect our incremental margins in the second half to be above our 25% target. Turning to the segment outlook. Based upon MP's successful mitigation of persistent input costs, supply chain challenges, and first half performance, we are increasing the operating margin range to 14.8% to 15.3% with relatively balanced margins throughout the second half of 2022. For AWP, supply chain challenges continue to be more disruptive in this segment with the majority of our total hospital inventory. This segment has been performing well, and we expect sequential quarterly margin improvement to continue through the balance of 2022. Therefore, we have increased the bottom end of the margin range to 8% and maintained the top end of 8.5%. We are extremely pleased to be in a position to raise our earnings per share outlook to $3.80 to $4.20. And with that, I will turn it back to you, John.